Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

OBJECTIVE--To determine whether epoprostenol (prostacyclin, PGI2) or heart-lung transplantation (HLT), or both improves survival of patients with severe pulmonary hypertension. DESIGN--This was a prospective study where the effects of epoprostenol were compared with conventional treatment. Also, the...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British Heart Journal Ročník 70; číslo 4; s. 366 - 370
Hlavní autoři:	Higenbottam, T W, Spiegelhalter, D, Scott, J P, Fuster, V, Dinh-Xuan, A T, Caine, N, Wallwork, J
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BMJ Publishing Group Ltd and British Cardiovascular Society 01.10.1993 BMJ BMJ Publishing Group LTD
Témata:	Adult Biological and medical sciences Cardiovascular system Combined Modality Therapy Epoprostenol - therapeutic use Female Heart-Lung Transplantation Humans Hypertension, Pulmonary - drug therapy Hypertension, Pulmonary - mortality Hypertension, Pulmonary - surgery Hypertension, Pulmonary - therapy Male Medical sciences Pharmacology. Drug treatments Prospective Studies Survival Rate Vasodilator agents. Cerebral vasodilators Heart Human Vasodilator agent Prostaglandin I2 Respiratory disease Treatment efficiency Lung Cardiovascular disease Transplantation Homotransplantation Pulmonary hypertension Chemotherapy Treatment Surgery Comparative study
ISSN:	0007-0769, 1468-201X, 2053-5864
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!